WebFeb 11, 2014 · Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Cubist Pharmaceuticals, Inc. (CBSTZ) … WebApr 6, 2024 · Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday, February, 28th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.30. The company had revenue of $61.88 million for the quarter, compared to analysts' expectations of $47.18 million.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average …
WebDec 8, 2014 · News of the deal sent Cubist's share price surging by more than 34 percent, to $101.15, in premarket trading. Merck's stock price also rose more than 5 percent. WebApr 11, 2024 · 3 Wall Street research analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $36.00 to $44.00. On average, they predict the company's share price to reach $40.75 in the next year. This suggests a possible upside of 3.2% from the stock's current price. how many hammers does thor have
Merck to buy Cubist Pharmaceuticals for $9.5 billion - CNBC
WebApr 12, 2024 · Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating)’s stock price traded up 6.3% during mid-day trading on Tuesday after Piper Sandler raised their price target on the stock from $49.00 ... WebApr 6, 2024 · 14 brokers have issued 1 year price objectives for Apellis Pharmaceuticals' shares. Their APLS share price forecasts range from $40.00 to $139.00. On average, they predict the company's share price to reach $78.40 in the next twelve months. This suggests that the stock has a possible downside of 0.5%. WebApr 11, 2024 · Cubist Systematic Strategies LLC now owns 40,323 shares of the biotechnology company’s stock valued at $2,092,000 after buying an additional 2,900 shares during the last quarter. Prudential... how about going to the movies